Biotech CEO: Sarbanes-Oxley audits stand in way of IPO – The Business Journal

July 26, 2012 Posted By: Leave a comment
The biggest complaint businesses have about the law is the cost of complying with Section 404 ... Without product revenue, biotech companies on the public market are forced to ask investors to pay for SOX reporting rather than scientific research.”
Subscribe to LegalLaw247.Com Newsletter

Leave a Reply

Your email address will not be published. Required fields are marked *

*

CAPTCHA Image

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>